Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 - PubMed (original) (raw)
Case Reports
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
Richard A Morgan et al. Mol Ther. 2010 Apr.
Abstract
In an attempt to treat cancer patients with ERBB2 overexpressing tumors, we developed a chimeric antigen receptor (CAR) based on the widely used humanized monoclonal antibody (mAb) Trastuzumab (Herceptin). An optimized CAR vector containing CD28, 4-1BB, and CD3zeta signaling moieties was assembled in a gamma-retroviral vector and used to transduce autologous peripheral blood lymphocytes (PBLs) from a patient with colon cancer metastatic to the lungs and liver, refractory to multiple standard treatments. The gene transfer efficiency into autologous T cells was 79% CAR(+) in CD3(+) cells and these cells demonstrated high-specific reactivity in in vitro coculture assays. Following completion of nonmyeloablative conditioning, the patient received 10(10) cells intravenously. Within 15 minutes after cell infusion the patient experienced respiratory distress, and displayed a dramatic pulmonary infiltrate on chest X-ray. She was intubated and despite intensive medical intervention the patient died 5 days after treatment. Serum samples after cell infusion showed marked increases in interferon-gamma (IFN-gamma), granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-10, consistent with a cytokine storm. We speculate that the large number of administered cells localized to the lung immediately following infusion and were triggered to release cytokine by the recognition of low levels of ERBB2 on lung epithelial cells.
Figures
**Figure 1
Expression of the ERBB2 CAR. Diagram of the ERBB2-CAR vector (MSGV1-4D5-CD8-28BBZ) used in this trial is as shown on the top of the figure. As described in Materials and Methods section, patient PBMC were stimulated to induced T-cell division and then transduced with the CAR vector. Four days before cell infusion samples were removed for analysis of _ERBB2_-CAR gene expression by FACS (along with the CD3, CD4, or CD8 T-cell markers). CAR, chimeric antigen receptor; LTR, long terminal repeats; PBMC, peripheral blood mononuclear cell; scFv, single-chain Fv fragment.
**Figure 2
Serum cytokine levels. Serum samples obtained at the approximate times indicated after cell infusion were assayed for cytokine expression using commercial ELISA kits for cytokines IL-6, TNF-α, GM-CSF, and IFN-γ. The levels of cytokine IL-10 were independently determined by cytokine array (SearchLight) assay. All samples were diluted as necessary as to be in the linear range of the assay. ELISA, enzyme-linked immunosorbent assay; GM-CSF, granulocyte macrophage-colony stimulating factor; IFN-γ, interferon-γ IL, interleukin; TNF-α, tumor necrosis factor-α.
**Figure 3
Cytokine genotype. DNA extracted for patient PBMC was subject to PCR with sequence-specific primers (PCR-SSP) as described in Materials and Methods section. Primer pairs are designed to have perfect matches only with a single allele or group of alleles. Matched primer pairs result in the amplification of target sequences (i.e., a positive amplification band), whereas mismatched primer pairs do not result in amplification (i.e., a negative result). The specific genotypes detected by the SSP are shown above each lane (Neg cntl, reaction without cytokine primers). Shown is one of duplicate determinations. IFN-γ, interferon-γ IL, interleukin; SNP, single-nucleotide polymorphism; TNF-α, tumor necrosis factor-α.
**Figure 4
In vitro cytokine production. An aliquot of the ErbB2-CAR transduced (CAR) T lymphocytes infused into the patient or untransduced control T cells (UnTd) where assayed for IFN-γ cytokine production following overnight coculture with the indicated cell lines. ErbB2+ target cells were SK-OV3, SK-BR3, and MDA361. ErbB2− tumor lines were MDA468 and CCRF-CEM (CEM). Primary cells adapted for growth in culture were HDF, human diploid fibroblast, HUVEC, human umbilical vein endothelial cells; EBV-B-EBV transformed B cell line, NHBE, normal human bronchial/tracheal epithelial cells; PrEC, human prostate epithelial cells, HSMM, human skeletal muscle myoblasts, keratinocytes-human keratinocytes, HMEC, human mammary epithelial cells, and HRE, human renal epithelial cells. Autologous patient cells were auto-DC-patient 6-day dendritic cell culture, and auto-mac-patient 6-day macrophage culture. All samples were diluted as necessary as to be in the linear range of the assay (sample SK-OV3 was off-scale in this assay and the value from a repeat determination was as indicated). CAR, chimeric antigen receptor; IFN-γ, interferon-γ.
Comment in
- Safer CARS.
Heslop HE. Heslop HE. Mol Ther. 2010 Apr;18(4):661-2. doi: 10.1038/mt.2010.42. Mol Ther. 2010. PMID: 20357776 Free PMC article. No abstract available.
Similar articles
- A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.
Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. Zhao Y, et al. J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447. J Immunol. 2009. PMID: 19843940 Free PMC article. - Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y. Sun M, et al. Breast Cancer Res. 2014 Jun 11;16(3):R61. doi: 10.1186/bcr3674. Breast Cancer Res. 2014. PMID: 24919843 Free PMC article. - Gene therapy of malignant solid tumors by targeting erbB2 receptors and by activating T cells.
Hu WX, Chen HP, Yu K, Shen LX, Wang CY, Su SZ, Sui WJ, Shan DM, Li HZ. Hu WX, et al. Cancer Biother Radiopharm. 2012 Dec;27(10):711-8. doi: 10.1089/cbr.2012.1246. Epub 2012 Sep 18. Cancer Biother Radiopharm. 2012. PMID: 22988969 Free PMC article. - Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA, Reidy A, Mirandola L, Trotter K, Suvorava N, Figueroa A, Konala V, Aulakh A, Littlefield L, Grizzi F, Rahman RL, Jenkins MR, Musgrove B, Radhi S, D'Cunha N, D'Cunha LN, Hermonat PL, Cobos E, Chiriva-Internati M. Figueroa JA, et al. Int Rev Immunol. 2015 Mar;34(2):154-87. doi: 10.3109/08830185.2015.1018419. Int Rev Immunol. 2015. PMID: 25901860 Review. - CAR T-cell therapy of solid tumors.
Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH. Yong CSM, et al. Immunol Cell Biol. 2017 Apr;95(4):356-363. doi: 10.1038/icb.2016.128. Epub 2016 Dec 22. Immunol Cell Biol. 2017. PMID: 28003642 Review.
Cited by
- Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.
Ahmed EN, Cutmore LC, Marshall JF. Ahmed EN, et al. Cancers (Basel). 2024 Sep 18;16(18):3186. doi: 10.3390/cancers16183186. Cancers (Basel). 2024. PMID: 39335157 Free PMC article. Review. - CAR T cells in solid tumors and metastasis: paving the way forward.
Sirini C, De Rossi L, Moresco MA, Casucci M. Sirini C, et al. Cancer Metastasis Rev. 2024 Sep 24. doi: 10.1007/s10555-024-10213-7. Online ahead of print. Cancer Metastasis Rev. 2024. PMID: 39316265 Review. - CAR-T Cells in the Treatment of Nervous System Tumors.
Testa U, Castelli G, Pelosi E. Testa U, et al. Cancers (Basel). 2024 Aug 22;16(16):2913. doi: 10.3390/cancers16162913. Cancers (Basel). 2024. PMID: 39199683 Free PMC article. Review. - CD8+ T Cell Biology in Cytokine Storm Syndromes.
Sekine T, Galgano D, Casoni GP, Meeths M, Cron RQ, Bryceson YT. Sekine T, et al. Adv Exp Med Biol. 2024;1448:129-144. doi: 10.1007/978-3-031-59815-9_10. Adv Exp Med Biol. 2024. PMID: 39117812 Review. - Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer.
Zeng S, Jin N, Yu B, Ren Q, Yan Z, Fu S. Zeng S, et al. BMC Gastroenterol. 2024 Aug 6;24(1):249. doi: 10.1186/s12876-024-03286-9. BMC Gastroenterol. 2024. PMID: 39107717 Free PMC article.
References
- Rubin I., and , Yarden Y.2001The basic biology of HER2 Ann Oncol 12(suppl. 1): S3–S8. - PubMed
- Yarden Y., and , Shilo BZ. SnapShot: EGFR signaling pathway. Cell. 2007;131:1018. - PubMed
- Yarden Y., and , Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137. - PubMed
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712. - PubMed
- Ross JS., and , McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19:554–568. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous